PEG-MGF
PEG-MGF is a synthetic pegylated analog of Mechano Growth Factor, a splice variant of IGF-1 your skeletal muscle produces in response to mechanical stress or injury. Native MGF degrades in plasma within minutes. PEGylation extends its half-life to 24 to 72 hours, enabling systemic administration and preclinical investigation across muscle regeneration, tissue repair, bone healing, and cardiac recovery. No human clinical trials have been completed for PEG-MGF in any indication. We work with it accordingly.
Important status notice. PEG-MGF is not FDA approved for any therapeutic use. PEG-MGF was previously classified as a Category 2 bulk drug substance under the FDA's interim 503A list. That Category 2 designation was removed on April 22, 2026, after the nominator withdrew the nomination. Standard 503A pharmacy regulations now apply. The FDA will consult the Pharmacy Compounding Advisory Committee (PCAC) before the end of February 2027 on potential inclusion of PEG-MGF on the 503A bulks list. Any use at Paragon is research-informed, under direct physician supervision, and only after a full clinical review.
WADA Anti-Doping Status. PEG-MGF is prohibited under WADA S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics. IGF-1 and all its variants and analogs are explicitly covered. Prohibited at all times, in and out of competition, in every WADA-regulated sport.
.jpeg)
.jpeg)
Overview
MGF is produced by alternative splicing of the IGF-1 gene in response to mechanical load or tissue damage. Its primary function is to activate quiescent satellite cells, the muscle stem cells your body uses to repair damaged fibers, and expand the pool of myogenic precursors before mature IGF-1 drives their differentiation. The MGF E-peptide carries autonomous biological activity independent of the IGF-1 receptor, making PEG-MGF a coordinator of the full repair cascade rather than simply an anabolic stimulus.
Native MGF has a plasma half-life of approximately five to seven minutes. PEGylation, the attachment of polyethylene glycol chains, extends this to approximately 24 to 72 hours, improves solubility, and enables subcutaneous administration with meaningful tissue exposure. Detection in plasma and urine is possible using specialized assay methods. WADA tests for MGF and its analogs in anti-doping programs. The preclinical research base is consistent across multiple tissue systems. The human clinical story does not yet exist, and we say that plainly before anything else.
Chemical structure & Properties
- Core Sequence (24 aa): Tyr-Gln-Pro-Pro-Ser-Thr-Asn-Lys-Asn-Thr-Lys-Ser-Gln-Arg-Arg-Lys-Gly-Ser-Thr-Phe-Glu-Glu-Arg-Lys
- Molecular Formula (Core): C₁₂₁H₂₀₀N₄₂O₃₉
- Molecular Weight: ~2,867 Da core; ~4,000 to 6,000 Da with PEG conjugation
- Origin: Synthetic analog of MGF (IGF-1Ec), C-terminal fragment of IGF-1
- Half-Life (Native MGF): ~5 to 7 minutes in plasma
- Half-Life (PEG-MGF): ~24 to 72 hours
- Route: Subcutaneous injection
- Storage: Lyophilised powder; 2°C to 8°C before reconstitution
- WADA Status: Prohibited, S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics)
Mechanism of Action
PEG-MGF exerts its biological effects through multiple interconnected molecular mechanisms rooted in IGF-1 splice variant biology:
Clinical Applications and
Research Evidence
Current Clinical Evidence
Safety Considerations
Regulatory Status and
Legal Considerations
Global Regulatory Status
- Not FDA approved for any therapeutic indication
- Previously Category 2 on the 503A interim list; that designation was removed on April 22, 2026
- Standard 503A pharmacy regulations now apply
- PCAC consultation expected before February 2027 on potential 503A bulks list inclusion
- 503B (outsourcing facilities) status is addressed separately; discuss sourcing during consultation
WADA Anti-Doping Status
- Category: S2, Peptide Hormones, Growth Factors, Related Substances, and Mimetics
- IGF-1 and all variants, splice variants, and analogs explicitly covered
- Prohibited at all times, in and out of competition, every WADA-regulated sport
- Urine and blood testing available for anti-doping purposes
Legal Availability
- Research use legal in the United States for non-competing adults
- Not approved as a therapeutic, which is a distinct question from legality
- Any use at Paragon is research-informed and under direct physician supervision
- Source, quality, and chain of custody reviewed during consultation
Administration and Dosing
Considerations
The Paragon Method: Step-by-Step
- Administered by subcutaneous injection, typically near the target tissue site
- Dose, frequency, and cycle length determined by your clinician based on your labs, goals, and relevant research
- We do not publish a standard dose. The research literature reports a wide range across indications, and a number appropriate for acute injury recovery is not appropriate for sarcopenia management
- Cancer screening is a required part of intake before prescribing any IGF-pathway compound
- For musculoskeletal injury recovery, we coordinate with your orthopedic specialist
.jpeg)
- Phase 1 safety, tolerability, and pharmacokinetic studies in healthy adult volunteers
- Characterization of non-IGF-1R E-peptide pathways in satellite cell activation
- Dose-response relationships across tissue types and administration routes
- Long-term effects of repeated dosing on satellite cell pool size and muscle quality
- Efficacy studies in sarcopenia, injury recovery, and cardiac rehabilitation
Conclusion
Every plan at Paragon starts the same way: a full intake, current labs, and a clear conversation about what you want to change. From that foundation, we evaluate the tools available. PEG‑MGF is one option, but it is never assumed. If it proves to be the right fit for your situation, we will say so directly. If it does not, we will be equally transparent, pointing you toward interventions that better serve your physiology, your goals, and the outcomes that matter most.
Our role is not to promote a single compound, but to help you navigate the complexity of human performance with clarity and precision. Every recommendation is grounded in evidence, tailored to your biology, and focused on building a plan that creates lasting progress.
PEG-MGF SCIENTIFIC
DATA SUMMARY
Disclaimer: This information is provided for educational purposes only and does not constitute medical advice. PEG-MGF is not approved by the FDA or any major regulatory authority for any therapeutic indication. It is prohibited under WADA S2 and must not be used by anyone competing in a WADA-regulated sport. Its 503A compounding status changed on April 22, 2026, when the FDA removed PEG-MGF from Category 2. A PCAC advisory consultation is expected before the end of February 2027 regarding potential inclusion of PEG-MGF on the 503A bulks list. Any use at Paragon is research-informed and under direct physician supervision, for non-competing adults only. Patients should consult with a qualified clinician and ensure regulatory compliance before considering any use of PEG-MGF.